Financial Data and Key Metrics Changes - For the fourth quarter of 2025, the company reported operating expenses of $91.9 million, which included $90.4 million in non-cash stock-based compensation. Excluding stock-based compensation, operating expenses were $72.5 million [26] - For the year ended 2025, total operating expenses were $384.6 million, including $75.6 million in non-cash stock-based compensation, leading to adjusted operating expenses of $309 million [27] - The company ended 2025 with $368 million in cash and cash equivalents, bolstered by $60.4 million from the exercise of warrants [11][27] Business Line Data and Key Metrics Changes - The company is focused on the launch of apitegromab, the world's first muscle-targeted therapy for SMA, with preparations underway for a U.S. launch in 2026 [4][11] - The company is also advancing its anti-myostatin pipeline, including apitegromab and SRK-439, with ongoing clinical trials and promising data from phase 1 studies [10][20] Market Data and Key Metrics Changes - The global market for SMA therapies is currently valued at nearly $5 billion in annual sales, with a significant unmet need for muscle-targeted therapies [21] - The company is engaging with approximately 140 SMA treatment centers and 2,600 prescribing physicians in the U.S. to enhance disease education and awareness [22] Company Strategy and Development Direction - The company aims to deliver apitegromab to the SMA community as quickly as possible while also expanding its pipeline for other rare neuromuscular diseases [4][12] - The company is building a 50-country operating platform in Europe and enhancing its commercial capabilities to support the launch of apitegromab [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing engagement with the FDA and the urgency to bring apitegromab to market, reaffirming guidance for BLA resubmission and U.S. launch in 2026 [7][29] - The company remains focused on long-term shareholder value while navigating the complexities of regulatory approvals and market readiness [28][91] Other Important Information - The company secured a new debt facility for up to $550 million to support its commercial and R&D priorities, with immediate access to $100 million [11][28] - The company is preparing for a supplemental BLA submission for a second fill-finish facility later in 2026 [14][27] Q&A Session Summary Question: Is Novo now ready for re-inspection? - Management confirmed that the gating item is a successful re-inspection of the Catalent Indiana facility, which would trigger the BLA resubmission [33][34] Question: What happens if the backup facility is needed? - Management indicated that whether it is a supplemental BLA or a fallback to the backup facility, they do not expect significant delays in timelines [36][37] Question: What was the purpose of the FDA sending a field team? - Management noted that the field team's visit indicates the FDA's high priority on the remediation of the Catalent facility and the urgency to progress the apitegromab file [40][42] Question: What are the expectations for the label regarding age subgrouping? - Management anticipates a straightforward alignment with the FDA on the final label after BLA resubmission, considering the comprehensive data already presented [62] Question: What are the expectations for the launch trajectory? - Management expects robust demand for apitegromab but acknowledges potential access speed bumps due to payer reimbursement processes [69] Question: Will the MAA review be affected by the Catalent facility? - Management confirmed that progress with the FDA will positively influence the MAA review process with the EMA [81][82]

Financial Data and Key Metrics Changes - For Q4 2025, the company reported operating expenses of $91.9 million, including $90.4 million in non-cash stock-based compensation, while excluding stock-based compensation, operating expenses were $72.5 million [24] - For the full year 2025, operating expenses totaled $384.6 million, with $75.6 million in non-cash stock-based compensation, and $309 million when excluding stock-based compensation [25] - The company ended 2025 with $368 million in cash and cash equivalents, bolstered by $60.4 million from the exercise of warrants [9][25] Business Line Data and Key Metrics Changes - The company is focused on the commercial launch of apitegromab, the first muscle-targeted therapy for SMA, with preparations underway for a U.S. launch in 2026 [6][19] - The company is also advancing its anti-myostatin pipeline, including apitegromab and SRK-439, with ongoing clinical trials and promising data from phase 1 studies [8][18] Market Data and Key Metrics Changes - The global market for SMA therapies is currently valued at nearly $5 billion in annual sales, with a significant unmet need for muscle strength and motor function treatments [20] - The company is engaging with approximately 140 SMA treatment centers and 2,600 prescribing physicians in the U.S. to enhance disease education and awareness [21] Company Strategy and Development Direction - The company aims to deliver apitegromab to the SMA community as quickly as possible while also expanding its pipeline for other rare neuromuscular diseases [3][10] - The company is building a 50-country operating platform in Europe and preparing for a launch in Germany in the second half of 2026 [10][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing engagement with the FDA and the urgency to bring apitegromab to market, anticipating a successful BLA resubmission following a reinspection of the Catalent Indiana facility [5][11] - The company remains focused on its strategic priorities and is optimistic about the transformative potential of its therapies for patients with SMA and other neuromuscular diseases [10][28] Other Important Information - The company secured a new debt facility for up to $550 million to support its commercial and R&D activities, with $100 million immediately available for use [25][27] - The company is also planning to monetize a Priority Review Voucher to further strengthen its balance sheet [27] Q&A Session Summary Question: Is Novo now ready for re-inspection? - Management confirmed that the gating item is a successful re-inspection of the Catalent Indiana facility, which would trigger the BLA resubmission [31][32] Question: What would happen if the backup facility is needed? - Management indicated that whether it is a supplemental BLA or a primary filing, they do not expect significant delays in timelines [34][36] Question: What was the purpose of the FDA sending a field team? - Management noted that the field team's visit indicates the FDA's high priority on the remediation of the Catalent facility and the urgency to bring apitegromab to patients [38][40] Question: What are the expectations for the label regarding age subgrouping? - Management anticipates a straightforward alignment with the FDA on the final label after BLA resubmission, given the progress made during the original review process [60] Question: What are the expectations for time to profitability? - Management indicated that they expect a typical rare disease revenue trajectory, leading to profitability within two to three years from launch [91]